Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Safety and immunogenicity of VLPCOV-02, a SARS-CoV-2 self-amplifying RNA vaccine with a modified base, 5-methylcytosine

22 Jan 2024

Abstract excerpt

Continuing emergence of variants of concern resulting in reduced SARS-CoV-2 vaccine efficacy necessitates additional prevention strategies. The structure of VLPCOV-01, a lipid nanoparticle-encapsulated, self-amplifying RNA COVID-19 vaccine with a comparable immune response to BNT162b2, was revised by incorporating a modified base, 5-methylcytosine, to reduce reactogenicity, and an updated receptor-binding domain...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to COVID-19 Clinical Research Studies
Share to SARS-CoV-2 and COVID-19 Research
Share to Viral gastroenteritis research and epidemiology

Methodology Data sources Editorial policy Privacy Delete account & data About Contact Helena Bioinformatics

Source

Identifiers

PMID: 38352232
DOI: 10.1016/j.isci.2024.108964

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 9 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Safety and immunogenicity of VLPCOV-02, a SARS-CoV-2 self-amplifying RNA vaccine with a modified base, 5-methylcytosinePMID 38352232Read ↗

A self-amplifying RNA vaccine against COVID-19 with long-term room-temperature stabilitySemantic proximity Read ↗

Optimization of non-coding regions for a non-modified mRNA COVID-19 vaccineSemantic proximity Read ↗

Self-amplifying RNA SARS-CoV-2 lipid nanoparticle vaccine candidate induces high neutralizing antibody titers in miceSemantic proximity Read ↗

Phase 1/2 Study to Describe the Safety and Immunogenicity of a COVID-19 RNA Vaccine Candidate (BNT162b1) in Adults 18 to 55 Years of Age: Interim ReportSemantic proximity Read ↗

Optimization of Non-Coding Regions Improves Protective Efficacy of an mRNA SARS-CoV-2 Vaccine in Nonhuman PrimatesSemantic proximity Read ↗

Universal protection against SARS-CoV-2 viruses by multivalent mRNA vaccine in miceSemantic proximity Read ↗

Safety and Immunogenicity of an Inactivated Whole Virion SARS-CoV-2 Vaccine, TURKOVAC, in Healthy Adults: Interim Results from Randomised, Double-Blind, Placebo-Controlled Phase 1 and 2 TrialsSemantic proximity Read ↗

The Preclinical Evaluation of Self-Replicating RNA Oral Vaccine to Simultaneously Neutralize Both SARS-CoV-2 Delta and Alpha VariantsSemantic proximity Read ↗

Safety and Immunogenicity of CpG 1018 and Aluminium Hydroxide-Adjuvanted SARS-CoV-2 S-2P Protein Vaccine MVC-COV1901: A Large-Scale Double-Blind, Randomised, Placebo-Controlled Phase 2 TrialSemantic proximity Read ↗

Circular RNA vaccines against SARS-CoV-2 and emerging variantsSemantic proximity Read ↗

SARS-CoV-2 will constantly sweep its tracks: a vaccine containing CpG motifs in 'lasso' for the multi-faced virus.Semantic proximity Read ↗

Boosting of SARS-CoV-2 immunity in nonhuman primates using an oral rhabdoviral vaccineSemantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.